Potential new methods for antiepileptic drug delivery

CNS Drugs

Volumn 16, Issue 9, 2002, Pages 579-593

  Fisher, Robert S ^a   Ho, Jet ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DP 16; GABAPENTIN; LAMOTRIGINE; LIPOSOME; NANOPARTICLE; PHENYTOIN; PHOSPHOLIPASE; TOPIRAMATE; TRANSFERRIN; UNCLASSIFIED DRUG; VALPROIC ACID; VALPROIC ACID DERIVATIVE; VIGABATRIN; ZONISAMIDE;

ADENOVIRUS; ANTICONVULSANT ACTIVITY; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BRAIN REGION; CELL SURVIVAL; CELL TRANSPLANTATION; CELL VIABILITY; CONTINUOUS INFUSION; CONTROLLED DRUG RELEASE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOXICITY; ELECTROENCEPHALOGRAM; EMERGENCY TREATMENT; EPILEPSY; GENE THERAPY; GINGIVA HYPERPLASIA; HERPES VIRUS; HUMAN; LIVER TOXICITY; NEPHROLITHIASIS; NEUROMODULATION; NEUROTRANSMITTER RELEASE; PANCREATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; RETINA DISEASE; REVIEW; THEORY; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0036351947     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216090-00001     Document Type: Review

References (125)

1. Lamotrigine-induced severe cutaneous adverse reactions
2. Visual function loss from vigabatrin: Effect of stopping the drug
3. The mechanisms of action of commonly used antiepileptic drugs
4. Effectiveness of first antiepileptic drug
5. Emerging protein delivery methods
6. Potential use of non-classical pathways for the transport of macromolecular drugs
7. A comparison of four treatments for generalized convulsive status epilepticus
8. Fosphenytoin (Cerebyx®)
9. Safety of intravenous valproate
10. New formulations of drugs in epilepsy
11. Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state
12. A new injectable carbamazepine solution: Antiepileptic effects and pharmaceutical properties
13. Intravenous carbamazepine: Comparison of different parenteral formulations in a mouse model of convulsive status epilepticus
14. Pediatric use of intravenous and intramuscular phenytoin: Lessons learned
15. The use of phenobarbitone in the management of agitation and seizures at the end of life
16. Subcutaneous midazolam, diamorphine and hyoscine infusion in palliative care of a child with neurodegenerative disease
17. Continuous subcutaneous insulin infusion therapy for children and adolescents: An option for routine diabetes care
18. Modeling transdermal drug release
19. Enhancement of transdermal drug delivery: Chemical and physical approaches
20. Home and hospital treatment of acute seizures in children with nasal midazolam
21. Sublingual midazolam premedication in children: A dose response study
22. Comparison between three transmucosal routes of administration of midazolam in children
23. The biopharmaceutical aspects of nasal mucoadhesive drug delivery
24. Cyclodextrin solubilization of benzodiazepines: Formulation of midazolam nasal spray
25. Nasal rather than rectal benzodiazepines in the management of acute childhood seizures?
26. Nasal midazolam effects on childhood acute seizures
27. Midazolam for premedication in children: Nasal vs rectal administration
28. Pharmacokinetics of rectal drug administration. Part I: General considerations and clinical applications of centrally acting drugs
29. Rectal diazepam for prehospital pediatric status epilepticus
30. Treatment of status epilepticus in children with rectal sodium valproate
31. Treating repetitive seizures with a rectal diazepam formulation: A randomized study
32. Development of inhalational agents for oncologic use
33. A review of the technical aspects of drug nebulization
34. Targeted delivery of inhaled drugs: Current challenges and future goals
35. Isoflurane for the management of status epilepticus
36. Rapid arrest of seizures with an inhalation aerosol containing diazepam
37. Nasal mucoadhesive drug delivery
38. Cytotoxic chemotherapy: Advances in delivery, pharmacology, and testing
39. Brain drug technologies: Novel approaches for transporting therapeutics
40. Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium
41. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans
42. Technology evaluation: Electroporation therapy, Genetronics Inc.
43. Epilepsy and the blood brain barrier: Endothelial cell responses to seizures
44. Progress report on new antiepileptic drugs: A summary of the Fifth Eilat Conference (EILAT V)
45. Permeable endothelium and the interstitial space of brain
46. Convection-enhanced delivery of macromolecules in the brain
47. Variables affecting convection-enhanced delivery to the striatum: A systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time
48. Intrathecal drug therapy
49. Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: A preliminary report
50. Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: Experience with an intrathecal drug delivery system
51. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: Long-term benefits and efficacy
52. Rapid cessation of focally induced generalized seizures in rats through microinfusion of lidocaine hydrochloride into the focus
53. Antiepileptic effects of focal micro-injection of excitatory amino acid antagonists
54. The use of microdialysis in CNS drug delivery studies: Pharmacokinetic perspectives and results with analgesics and antiepileptics
55. Local perfusion of diazepam attenuates interictal and ictal events in the bicuculline model of epilepsy in rats
56. Interictal and ictal activity in the rat cobalt/pilocarpine model of epilepsy decreased by local perfusion of diazepam
57. An automated drug delivery system for focal epilepsy
58. Real-time automated detection and quantitative analysis of seizures and short-term prediction of clinical onset
59. Responsive polymeric delivery systems
60. Local drug delivery
61. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
62. Seizure suppression in kindling epilepsy by intracerebral implants of GABA-but not by noradrenaline-releasing polymer matrices
63. Interstitial delivery of diphenylhydantoin in the brain for the treatment of seizures in a rat model
64. Cell replacement therapies for central nervous system disorders
65. Cell delivery to the central nervous system
66. Cellular transplants as sources for therapeutic agents
67. Integration of hippocampal suspension grafts with host neocortex
68. Transplantation of neural stem cells: Cellular & gene therapy for hypoxic-ischemic brain injury
69. New prospects for human stem-cell therapy in the nervous system
70. Encapsulated neural transplants
71. Fetal brain tissue grafts modulate neuronal excitability in a chronic model of epilepsy
72. Permanently altered hippocampal structure, excitability, and inhibition after experimental status epilepticus in the rat: The 'dormant basket cell' hypothesis and its relevance to temporal lobe epilepsy
73. Pattern of long-distance projections from fetal hippocampal field CA3 and CA1 cell grafts in lesioned CA3 of adult hippocampus follows intrinsic character of respective donor cells
74. Minireview: Kainic acid as a tool for the study of temporal lobe epilepsy
75. Fetal hippocampal grafts containing CA3 cells restore host hippocampal glutamate decarboxylase-positive interneuron numbers in a rat model of temporal lobe epilepsy
76. Seizure suppression in kindling epilepsy by grafts of fetal GABAergic neurons in rat substantia nigra
77. Xenotransplantation for CNS repair: Immunological barriers and strategies to overcome them
78. Porcine fetal GABA-producing neural cell transplants for human partial-onset seizures: Safety and feasibility
79. Genetics of the epilepsies
80. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1)
81. Gene therapy for brain tumors: The fundamentals
82. Potential of gene therapy for brain tumors
83. From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system
84. Viral vectors for gene therapy in Parkinson's disease
85. Gene therapeutic strategies for neurodegenerative diseases
86. The future of gene therapy for stroke
87. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors. Part II: Vector systems and applications
88. Extended release of adenovirus from polymer microspheres: Potential use in gene therapy for brain tumors
89. Adeno-associated viral vectors for gene transfer and gene therapy
90. Gene therapy in the central nervous system: The use of recombinant retroviruses
91. Lentiviral vectors: Regulated gene expression
92. Principles of gene therapy: Potential applications in the treatment of cerebral ischaemia
93. Gene targeting technology and gene therapy of the brain
94. Gene therapy for treatment of cerebral ischemia using defective herpes simplex viral vectors
95. Nonviral gene delivery to the lateral ventricles in rat brain: Initial evidence for widespread distribution and expression in the central nervous system
96. Peptide-mediated cellular delivery
97. Gene transfer into the central nervous system using herpes simplex virus-1 vectors
98. Use of herpes simplex virus type 1 for transgene expression within the nervous system
99. Calbindin d28k over-expression protects striatal neurons from transient focal cerebral ischemia
100. Neuroprotection with herpes simplex vectors expressing virally derived anti-apoptotic agents
101. Suicide gene therapy: Possible applications in haematopoietic disorders
102. Demyelination but no cognitive, motor or behavioral deficits after adenovirus-mediated gene transfer into the brain
103. Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity
104. Adenovirus-mediated transfer and expression of beta-gal in injured hippocampus after traumatic brain injury in mice
105. Direct delivery of leptin to the hypothalamus using recombinant adeno-associated virus vectors results in increased therapeutic efficacy
106. Gene transfer with lipospermines and polyethylenimines
107. Virosomes: Evolution of the liposome as a targeted drug delivery system
108. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease
109. Noninvasive gene targeting to the brain
110. Trend and developments in liposome drug delivery systems
111. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors
112. Binding of daidzein to liposomes
113. Potential usage of thermosensitive liposomes for site-specific delivery of cytokines
114. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs
115. Vasuclar permeability in a human tumor xenograft: Molecular size dependence and cutoff size
116. The cell biology of the blood brain barrier
117. Delivery of peptides and proteins through the blood-brain barrier
118. Anthrax toxin fusion proteins for intracellular delivery of macromolecules
119. Molecular motors and their role in membrane traffic
120. Host regulation of noradrenaline release from grafts of seizure-suppressant locus coeruleus neurons
121. Suppression of kindling epileptogenesis in rats by intrahippocampal cholinergic grafts
122. Fetal raphe transplants reduce seizure severity in serotonin-depleted GEPRs
123. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy